Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CLNNW logo CLNNW
Upturn stock ratingUpturn stock rating
CLNNW logo

Clene Inc (CLNNW)

Upturn stock ratingUpturn stock rating
$0.02
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CLNNW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.02
high$

Analysis of Past Performance

Type Stock
Historic Profit -70%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 646.98M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.48
52 Weeks Range 0.02 - 0.08
Updated Date 05/16/2025
52 Weeks Range 0.02 - 0.08
Updated Date 05/16/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -5032.1%

Management Effectiveness

Return on Assets (TTM) -49.62%
Return on Equity (TTM) -1738.36%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 6140786
Shares Outstanding -
Shares Floating 6140786
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Clene Inc

stock logo

Company Overview

overview logo History and Background

Clene Inc., founded in 2012, is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases using a unique nanocatalysis platform. They are publicly traded on the Nasdaq under the ticker symbol CLNN.

business area logo Core Business Areas

  • Neurodegenerative Disease Therapeutics: Clene focuses on developing drugs to treat neurodegenerative diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease, using their proprietary catalytic nanocrystal platform.

leadership logo Leadership and Structure

Rob Etherington is the current CEO. The company has a board of directors that oversees corporate governance. The operational structure involves research and development, clinical trials, and regulatory affairs divisions.

Top Products and Market Share

overview logo Key Offerings

  • CNM-Au8: CNM-Au8 is Clene's lead drug candidate, an oral suspension of gold nanocrystals being developed for the treatment of neurodegenerative diseases such as multiple sclerosis and amyotrophic lateral sclerosis. There is not a publicly known market share for CNM-Au8 since it is not approved. Main competitors include disease-modifying therapies offered by pharmaceutical giants like Biogen (BIIB) and Novartis (NVS).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry focused on neurodegenerative diseases is characterized by high unmet needs, substantial research and development investment, and rigorous regulatory requirements. The industry is highly competitive, with numerous companies pursuing novel therapies.

Positioning

Clene is positioned as an innovator using nanocatalysis to address neurodegenerative diseases. Its competitive advantage lies in its unique drug delivery system and potential to improve neuronal bioenergetics.

Total Addressable Market (TAM)

The global market for neurodegenerative disease therapeutics is projected to reach hundreds of billions of dollars. Clene aims to capture a portion of this market with its novel nanocatalytic therapies. Expected to reach $53.9 billion by 2030.

Upturn SWOT Analysis

Strengths

  • Novel nanocatalysis platform
  • Proprietary drug delivery technology
  • Potential for improved bioenergetics
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Dependence on successful clinical trial outcomes
  • Lack of approved products
  • High R&D expenses

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Increased awareness of neurodegenerative diseases

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established therapies
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • BIIB
  • NVS
  • TEVA

Competitive Landscape

Clene faces significant competition from established pharmaceutical companies with approved therapies. Clene's competitive advantage lies in its novel nanocatalysis approach, which has the potential to provide superior efficacy and safety compared to existing treatments.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is defined by the progression of clinical trials, not revenue generation.

Future Projections: Future growth is dependent on successful clinical trial results, regulatory approvals, and commercialization efforts. Analyst expectations are varied due to the speculative nature of clinical-stage companies.

Recent Initiatives: Recent strategic initiatives include advancing clinical trials of CNM-Au8 in multiple sclerosis and ALS.

Summary

Clene Inc. is a high-risk, high-reward clinical-stage biopharmaceutical company. Its success depends on the successful development and commercialization of CNM-Au8 and other therapies utilizing its nanocatalysis platform. Positive clinical trial outcomes are essential for its future. Clene should focus on partnering and strategic funding to mitigate financial risks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Clene Inc. Investor Relations
  • SEC Filings
  • Analyst Reports
  • Company Website

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on individual risk tolerance and thorough due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Clene Inc

Exchange NASDAQ
Headquaters Salt Lake City, UT, United States
IPO Launch date 2020-12-31
CEO, President & Director Mr. Robert Etherington MBA
Sector Consumer Defensive
Industry Packaged Foods
Full time employees 75
Full time employees 75

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.